https://scholars.lib.ntu.edu.tw/handle/123456789/540383
標題: | Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases | 作者: | YUNG-MING CHEN SHUEI-LIONG LIN WEN-CHIH CHIANG KWAN-DUN WU TUN-JUN TSAI |
公開日期: | 2006 | 卷: | 69 | 期: | 8 | 起(迄)頁: | 1410-1415 | 來源出版物: | Kidney International | 摘要: | Proteinuria (albuminuria) reflects dysfunction of the glomerular permeability barrier in which inflammatory cytokines play a key role. Pentoxifylline (PTX) is a phosphodiesterase inhibitor that possesses potent anti-inflammatory and immunomudulatory effects. This study evaluated the effectiveness of PTX to reduce proteinuria and inflammatory mediators in patients with proteinuric primary glomerular diseases. Seventeen patients with primary glomerular diseases, a persistent spot proteinuria exceeding 1.5 g/g creatinine (Cr) and a glomerular filtration rate between 24 and 115 ml/min/1.73m2 were treated with PTX 400 mg twice daily for 6 months. Before and after the treatment, serum Cr, plasma renin activity and aldosterone concentrations, plasma and urinary tumor necrosis factor (TNF)-α, interleukin-1β and monocyte chemoattractant protein (MCP)-1, as well as urinary protein and Cr were measured. PTX significantly reduced urinary protein excretion, along with an increase of serum albumin. A significant correlation existed between the basal urinary protein/Cr and the basal urinary MCP-1/Cr ratios. PTX lowered the urinary MCP-1/Cr ratio, and the percent reduction of urinary protein/Cr ratio correlated directly with the precent decrease of urinary MCP-1/Cr ratio after PTX treatment. There was no significant change in blood pressure, renal function, biochemical parameters, plasma renin activity and aldosterone concentrations, or plasma TNF-α and MCP-1 levels during the study. In conclusion, administration of PTX 800 mg per day is safe and effective for reducing proteinuria in patients with proteinuric primary glomerular diseases. This beneficial effect occurs in close association with a reduction of urinary MCP-1 excretion. ? 2006 International Society of Nephrology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646128029&doi=10.1038%2fsj.ki.5000302&partnerID=40&md5=a247139b963be8070711258349f890a6 https://scholars.lib.ntu.edu.tw/handle/123456789/540383 |
ISSN: | 0085-2538 | DOI: | 10.1038/sj.ki.5000302 | SDG/關鍵字: | corticosteroid; creatinine; immunosuppressive agent; interleukin 1; monocyte chemotactic protein 1; pentoxifylline; phosphodiesterase inhibitor; tumor necrosis factor; adult; aged; aldosterone blood level; article; blood pressure; clinical article; cytokine production; drug efficacy; drug safety; enzyme linked immunosorbent assay; female; glomerulopathy; glomerulus filtration rate; human; immunomodulation; kidney function; male; plasma renin activity; priority journal; proteinuria; Adult; Aged; Aged, 80 and over; Aldosterone; Chemokine CCL2; Creatinine; Cytokines; Female; Glomerular Filtration Rate; Glomerulonephritis; Humans; Interleukin-1; Male; Middle Aged; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinuria; Renin; Time Factors; Tumor Necrosis Factor-alpha |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。